Subject
Gastroenterology,Oncology
Reference18 articles.
1. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer;Douillard;N Engl J Med,2013
2. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer;Peeters;Clin Cancer Res,2015
3. Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408) (abstract 3617);Patterson;J Clin Oncol,2013
4. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild type KRAS or RAS metastatic colorectal cancer;Kim;Br J Cancer,2016
5. PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer